Le Lézard
Classified in: Health
Subjects: MAV, CFG

/R E P E A T -- NOTICE TO THE MEDIA - Government of Canada to announce funding to help address harms related to substance use in London, Ontario/


LONDON, ON, March 22, 2024 /CNW/ - Arielle Kayabaga, Member of Parliament for London West, on behalf of the Honourable Ya'ara Saks, Minister of Mental Health and Addictions and Associate Minister of Health, will announce funding under the Substance Use and Addictions Program (SUAP) to benefit people living in London, Ontario.

There will be a media availability immediately following the announcement. 

Date
March 25, 2024

Time
9:30 a.m. (ET)

Location

Victoria Hospital
Zone B Entrance (Atrium)
800 Commissioners Road East
London, Ontario

SOURCE Health Canada (HC)


These press releases may also interest you

at 01:30
PARIS, FRANCE, 2 May 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Keira Driansky as EVP, President of North America, effective May 13, 2024. She will serve on the...

at 01:00
Management Report1 Q1 2024 highlights Strong performance in Perfumery & Beauty on good demand developmentGood performance in Taste, Texture & Health underpinned by market recoveryHealth, Nutrition & Care was soft, with improving momentum by end of...

at 00:01
Today, the Conference on Jewish Material Claims Against Germany (Claims Conference) launched a new digital campaign, #CancelHate. The campaign features Holocaust survivors reading Holocaust denial posts from across social media platforms. Each post...

at 00:00
With over four decades of nursing experience under her belt, Sherry Shaffer Ratajczak has witnessed firsthand the dedication of her colleagues in patient care. Yet, she observed a common misunderstanding: many are unaware of the extensive knowledge...

1 mai 2024
Today, a decision was issued by the Court of Appeals Division I in the State of Washington in Erickson v. Monsanto, ruling in Monsanto's favor on multiple grounds. This decision reverses the initial verdict of $185 million in its entirety and...

1 mai 2024
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Poseida Therapeutics, Inc.  today announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, "Xyphos") and Poseida have entered into a...



News published on and distributed by: